Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Superimposing incident sexually transmitted infections on HIV phylogram to investigate possible misclassification of men who have sex with men as heterosexuals in a cohort in Antwerp, Belgium.

Osbak KK, Meehan CJ, G Ribas S, Heyndrickx L, Ariën KK, Tsoumanis A, Florence E, Esbroeck MV, Fransen K, Kenyon CR.

Int J STD AIDS. 2019 Apr;30(5):486-495. doi: 10.1177/0956462418821752. Epub 2019 Feb 4.

PMID:
30999835
2.

In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients.

Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, De Spiegelaere W, Vandekerckhove L, Seguin-Devaux C, Vanham G.

AIDS. 2019 Mar 1;33(3):387-398. doi: 10.1097/QAD.0000000000002068.

PMID:
30702513
3.

Case report: tick-borne encephalitis (TBE) in a Belgian traveller returning from Germany.

Gils S, Frans J, Ho E, Smismans A, Vermylen P, Dewil M, Dejaegher L, Heyndrickx L, Ariën KK, Van Esbroeck M.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay078. No abstract available.

PMID:
30204901
4.

Zika Virus IgG in Infants with Microcephaly, Guinea-Bissau, 2016.

Rosenstierne MW, Schaltz-Buchholzer F, Bruzadelli F, Có A, Cardoso P, Jørgensen CS, Michiels J, Heyndrickx L, Ariën KK, Fischer TK, Fomsgaard A.

Emerg Infect Dis. 2018 May;24(5):948-950. doi: 10.3201/eid2405.180153.

5.

Can Zika virus antibodies cross-protect against dengue virus?

Ariën KK, Michiels J, Foqué N, Heyndrickx L, Van Esbroeck M.

Lancet Glob Health. 2018 May;6(5):e494. doi: 10.1016/S2214-109X(18)30122-0. No abstract available.

6.

Immunization with Clinical HIV-1 Env Proteins Induces Broad Antibody Dependent Cellular Cytotoxicity-Mediating Antibodies in a Rabbit Vaccination Model.

Karlsson I, Borggren M, Jensen SS, Heyndrickx L, Stewart-Jones G, Scarlatti G, Fomsgaard A.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):206-217. doi: 10.1089/AID.2017.0140. Epub 2017 Nov 17.

PMID:
28982260
7.

Visualization of X4- and R5-Tropic HIV-1 Viruses Expressing Fluorescent Proteins in Human Endometrial Cells: Application to Tropism Study.

Terrasse R, Memmi M, Palle S, Heyndrickx L, Vanham G, Pozzetto B, Bourlet T.

PLoS One. 2017 Jan 6;12(1):e0169453. doi: 10.1371/journal.pone.0169453. eCollection 2017.

8.

Development, Evaluation, and Integration of a Quantitative Reverse-Transcription Polymerase Chain Reaction Diagnostic Test for Ebola Virus on a Molecular Diagnostics Platform.

Cnops L, Van den Eede P, Pettitt J, Heyndrickx L, De Smet B, Coppens S, Andries I, Pattery T, Van Hove L, Meersseman G, Van Den Herrewegen S, Vergauwe N, Thijs R, Jahrling PB, Nauwelaers D, Ariën KK.

J Infect Dis. 2016 Oct 15;214(suppl 3):S192-S202. Epub 2016 May 30.

9.

Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity.

Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, Delrue I, Taminau J, Wiernicki B, De Groote P, Garg AD, Leybaert L, Grooten J, Bertrand MJ, Agostinis P, Berx G, Declercq W, Vandenabeele P, Krysko DV.

Cell Rep. 2016 Apr 12;15(2):274-87. doi: 10.1016/j.celrep.2016.03.037. Epub 2016 Mar 31.

10.

Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398.

Ariën KK, Venkatraj M, Michiels J, Joossens J, Vereecken K, Van der Veken P, Heeres J, De Winter H, Heyndrickx L, Augustyns K, Vanham G.

J Antimicrob Chemother. 2016 May;71(5):1159-68. doi: 10.1093/jac/dkv501. Epub 2016 Feb 4.

PMID:
26850721
11.

Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark.

Borggren M, Jensen SS, Heyndrickx L, Palm AA, Gerstoft J, Kronborg G, Hønge BL, Jespersen S, da Silva ZJ, Karlsson I, Fomsgaard A.

AIDS Res Hum Retroviruses. 2016 May;32(5):434-42. doi: 10.1089/AID.2015.0118. Epub 2016 Jan 7.

12.

Risk of Misinterpretation of Ebola Virus PCR Results After rVSV ZEBOV-GP Vaccination.

Cnops L, Gerard M, Vandenberg O, Van den Wijngaert S, Heyndrickx L, Willems E, Demeulemeester K, De Clerck H, Dediste A, Callens S, De Munter P, Vlieghe E, Bottieau E, Wuillaume F, Van Esbroeck M, Ariën KK.

Clin Infect Dis. 2015 Jun 1;60(11):1725-6. doi: 10.1093/cid/civ131. Epub 2015 Feb 18. No abstract available.

PMID:
25694650
13.

Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.

Uchtenhagen H, Schiffner T, Bowles E, Heyndrickx L, LaBranche C, Applequist SE, Jansson M, De Silva T, Back JW, Achour A, Scarlatti G, Fomsgaard A, Montefiori D, Stewart-Jones G, Spetz AL.

J Immunol. 2014 Jun 15;192(12):5802-12. doi: 10.4049/jimmunol.1301898. Epub 2014 May 14.

14.

TNF/TNF-R1 pathway is involved in doxorubicin-induced acute sterile inflammation.

Kaczmarek A, Krysko O, Heyndrickx L, Løve Aaes T, Delvaeye T, Bachert C, Leybaert L, Vandenabeele P, Krysko DV.

Cell Death Dis. 2013 Dec 12;4:e961. doi: 10.1038/cddis.2013.496. No abstract available.

15.

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium.

PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.

16.

The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.

Balla-Jhagjhoorsingh SS, Corti D, Heyndrickx L, Willems E, Vereecken K, Davis D, Vanham G.

PLoS One. 2013 Jul 17;8(7):e68863. doi: 10.1371/journal.pone.0068863. Print 2013.

17.

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.

Visciano ML, Tagliamonte M, Stewart-Jones G, Heyndrickx L, Vanham G, Jansson M, Fomsgaard A, Grevstad B, Ramaswamy M, Buonaguro FM, Tornesello ML, Biswas P, Scarlatti G, Buonaguro L; NGIN Consortium.

J Transl Med. 2013 Jul 8;11:165. doi: 10.1186/1479-5876-11-165.

18.

Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission.

Ariën KK, Venkatraj M, Michiels J, Joossens J, Vereecken K, Van der Veken P, Abdellati S, Cuylaerts V, Crucitti T, Heyndrickx L, Heeres J, Augustyns K, Lewi PJ, Vanham G.

J Antimicrob Chemother. 2013 Sep;68(9):2038-47. doi: 10.1093/jac/dkt166. Epub 2013 May 3.

PMID:
23645585
19.

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Moog C, Dereuddre-Bosquet N, Teillaud JL, Biedma ME, Holl V, Van Ham G, Heyndrickx L, Van Dorsselaer A, Katinger D, Vcelar B, Zolla-Pazner S, Mangeot I, Kelly C, Shattock RJ, Le Grand R.

Mucosal Immunol. 2014 Jan;7(1):46-56. doi: 10.1038/mi.2013.23. Epub 2013 Apr 17.

PMID:
23591718
20.

Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques.

Borggren M, Vinner L, Andresen BS, Grevstad B, Repits J, Melchers M, Elvang TL, Sanders RW, Martinon F, Dereuddre-Bosquet N, Bowles EJ, Stewart-Jones G, Biswas P, Scarlatti G, Jansson M, Heyndrickx L, Grand RL, Fomsgaard A.

Vaccines (Basel). 2013 Jul 19;1(3):305-27. doi: 10.3390/vaccines1030305.

21.

MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques.

Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, Augustijns P, Bouchemal K, Ponchel G, Ramos OH, Herrera C, Stefanidou M, Shattock R, Heyndrickx L, Vanham G, Kessler P, Le Grand R, Martin L.

PLoS Pathog. 2012;8(12):e1003071. doi: 10.1371/journal.ppat.1003071. Epub 2012 Dec 6.

22.

Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.

Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, Pasternak A, Florence E, Vanham G.

PLoS One. 2012;7(5):e37792. doi: 10.1371/journal.pone.0037792. Epub 2012 May 30.

23.

Molecular epidemiology of HIV-1 transmission in a cohort of HIV-1 concordant heterosexual couples from Dakar, Senegal.

Jennes W, Kyongo JK, Vanhommerig E, Camara M, Coppens S, Seydi M, Mboup S, Heyndrickx L, Kestens L.

PLoS One. 2012;7(5):e37402. doi: 10.1371/journal.pone.0037402. Epub 2012 May 17.

24.

International network for comparison of HIV neutralization assays: the NeutNet report II.

Heyndrickx L, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Ramaswamy M, Sattentau Q, Tolazzi M, Schuitemaker H, Willems B, Wrin T, Fenyö EM, Scarlatti G.

PLoS One. 2012;7(5):e36438. doi: 10.1371/journal.pone.0036438. Epub 2012 May 9.

25.

MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.

Grupping K, Selhorst P, Michiels J, Vereecken K, Heyndrickx L, Kessler P, Vanham G, Martin L, Ariën KK.

Retrovirology. 2012 May 2;9:36. doi: 10.1186/1742-4690-9-36.

26.

Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT.

Van den Bergh R, Morin S, Sass HJ, Grzesiek S, Vekemans M, Florence E, Tran HT, Imiru RG, Heyndrickx L, Vanham G, De Baetselier P, Raes G.

PLoS One. 2012;7(4):e35074. doi: 10.1371/journal.pone.0035074. Epub 2012 Apr 6.

27.

A novel high-throughput cellular screening assay for the discovery of HIV-1 integrase inhibitors.

Van Loock M, Meersseman G, Van Acker K, Van Den Eynde C, Jochmans D, Van Schoubroeck B, Dams G, Heyndrickx L, Clayton RF.

J Virol Methods. 2012 Feb;179(2):396-401. doi: 10.1016/j.jviromet.2011.11.029. Epub 2011 Dec 7.

PMID:
22172974
28.

Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained.

Balla-Jhagjhoorsingh SS, Willems B, Heyndrickx L, Heyndrickx L, Vereecken K, Janssens W, Seaman MS, Corti D, Lanzavecchia A, Davis D, Vanham G.

PLoS One. 2011;6(10):e25488. doi: 10.1371/journal.pone.0025488. Epub 2011 Oct 10.

29.

Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways.

Kaczmarek A, Brinkman BM, Heyndrickx L, Vandenabeele P, Krysko DV.

J Pathol. 2012 Mar;226(4):598-608. doi: 10.1002/path.3009. Epub 2011 Dec 5.

PMID:
21960132
30.

Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.

Haldar B, Burda S, Williams C, Heyndrickx L, Vanham G, Gorny MK, Nyambi P.

PLoS One. 2011 Feb 23;6(2):e17253. doi: 10.1371/journal.pone.0017253.

31.

Control of viral replication after cessation of HAART.

Van Gulck E, Heyndrickx L, Bracke L, Coppens S, Florence E, Buvé A, Lewi P, Vanham G.

AIDS Res Ther. 2011 Feb 11;8(1):6. doi: 10.1186/1742-6405-8-6.

32.

TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation.

Krysko DV, Kaczmarek A, Krysko O, Heyndrickx L, Woznicki J, Bogaert P, Cauwels A, Takahashi N, Magez S, Bachert C, Vandenabeele P.

Cell Death Differ. 2011 Aug;18(8):1316-25. doi: 10.1038/cdd.2011.4. Epub 2011 Feb 11.

33.

Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Selhorst P, Vazquez AC, Terrazas-Aranda K, Michiels J, Vereecken K, Heyndrickx L, Weber J, Quiñones-Mateu ME, Ariën KK, Vanham G.

Antimicrob Agents Chemother. 2011 Apr;55(4):1403-13. doi: 10.1128/AAC.01426-10. Epub 2011 Jan 31. Erratum in: Antimicrob Agents Chemother. 2011 Jul;55(7):3645.

34.

Unravelling the antigenic landscape of the HIV-1 subtype A envelope of an individual with broad cross-neutralizing antibodies using phage display peptide libraries.

Dieltjens T, Willems B, Coppens S, Van Nieuwenhove L, Humbert M, Dietrich U, Heyndrickx L, Vanham G, Janssens W.

J Virol Methods. 2010 Oct;169(1):95-102. doi: 10.1016/j.jviromet.2010.07.004. Epub 2010 Jul 14.

PMID:
20637241
35.

Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Dieltjens T, Heyndrickx L, Willems B, Gray E, Van Nieuwenhove L, Grupping K, Vanham G, Janssens W.

Retrovirology. 2009 Dec 14;6:113. doi: 10.1186/1742-4690-6-113.

36.

HIV type 1 subtype A envelope genetic evolution in a slow progressing individual with consistent broadly neutralizing antibodies.

Dieltjens T, Loots N, Vereecken K, Grupping K, Heyndrickx L, Bottieau E, Vanham G, Davis D, Janssens W.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1165-9. doi: 10.1089/aid.2008.0161.

PMID:
19886837
37.

International network for comparison of HIV neutralization assays: the NeutNet report.

Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G.

PLoS One. 2009;4(2):e4505. doi: 10.1371/journal.pone.0004505. Epub 2009 Feb 20.

38.

Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.

Nyambi P, Burda S, Urbanski M, Heyndrickx L, Janssens W, Vanham G, Nadas A.

AIDS Res Hum Retroviruses. 2008 Dec;24(12):1507-19. doi: 10.1089/aid.2008.0154.

39.

CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.

Van Herrewege Y, Morellato L, Descours A, Aerts L, Michiels J, Heyndrickx L, Martin L, Vanham G.

J Antimicrob Chemother. 2008 Apr;61(4):818-26. doi: 10.1093/jac/dkn042. Epub 2008 Feb 12.

PMID:
18270220
40.

Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Van Gulck ER, Vanham G, Heyndrickx L, Coppens S, Vereecken K, Atkinson D, Florence E, Kint I, Berneman ZN, Van Tendeloo V.

J Virol. 2008 Apr;82(7):3561-73. doi: 10.1128/JVI.02080-07. Epub 2008 Jan 30.

41.

Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays.

Heyndrickx L, Vermoesen T, Vereecken K, Kurth J, Coppens S, Aerts L, Ohagen A, Van Herrewege Y, Lewi P, Vanham G.

J Virol Methods. 2008 Mar;148(1-2):166-73. doi: 10.1016/j.jviromet.2007.11.009. Epub 2008 Jan 14.

PMID:
18192031
42.

Production of human immunodeficiency virus type 1 (HIV-1) pseudoviruses using linear HIV-1 envelope expression cassettes.

Beels D, Heyndrickx L, Vereecken K, Vermoesen T, Michiels L, Vanham G, Kestens L.

J Virol Methods. 2008 Jan;147(1):99-107. Epub 2007 Sep 29.

PMID:
17904649
43.

Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients.

Steyaert S, Heyndrickx L, Verhoye L, Vermoesen T, Donners H, Fransen K, Van Wanzeele F, Vandergucht B, Vanham G, Leroux-Roels G, Vanlandschoot P.

Antiviral Res. 2007 Aug;75(2):129-38. Epub 2007 Mar 6.

PMID:
17379323
44.

The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection.

Steyaert S, Verhoye L, Beirnaert E, Donners H, Fransen K, Heyndrickx L, Vanham G, Leroux-Roels G, Vanlandschoot P.

J Immunol Methods. 2007 Mar 30;320(1-2):49-57. Epub 2007 Jan 9.

PMID:
17258763
45.

A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides.

Van Herrewege Y, Michiels J, Waeytens A, De Boeck G, Salden E, Heyndrickx L, van den Mooter G, de Béthune MP, Andries K, Lewi P, Praet M, Vanham G.

Antiviral Res. 2007 May;74(2):111-24. Epub 2006 Nov 7.

PMID:
17097156
46.

Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells.

Van den Bosch GA, Van Gulck E, Ponsaerts P, Nijs G, Lenjou M, Apers L, Kint I, Heyndrickx L, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF.

J Immunother. 2006 Sep-Oct;29(5):512-23.

PMID:
16971807
47.

Performance evaluation of the two protease sequencing primers of the Trugene HIV-1 genotyping kit.

Ribas SG, Heyndrickx L, Ondoa P, Fransen K.

J Virol Methods. 2006 Aug;135(2):137-42. Epub 2006 Jun 13.

PMID:
16777242
48.

Mother-to-child transmission of different HIV-1 subtypes among ARV Naïve infected pregnant women in Nigeria.

Odaibo GN, Olaleye DO, Heyndrickx L, Vereecken K, Houwer K, Jassens W.

Rev Inst Med Trop Sao Paulo. 2006 Mar-Apr;48(2):77-80. Epub 2006 May 8.

49.

Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones.

Ariën KK, Gali Y, El-Abdellati A, Heyndrickx L, Janssens W, Vanham G.

Virology. 2006 Mar 30;347(1):65-74. Epub 2005 Dec 28.

50.

Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.

Cham F, Zhang PF, Heyndrickx L, Bouma P, Zhong P, Katinger H, Robinson J, van der Groen G, Quinnan GV Jr.

Virology. 2006 Mar 30;347(1):36-51. Epub 2005 Dec 27.

Supplemental Content

Loading ...
Support Center